Clinical Report: Harrow's Vevye Access for All Program and Patient Access

Overview

Harrow's Vevye Access for All program aims to enhance patient access to Vevye (cyclosporine ophthalmic solution 0.1%) by reducing costs and administrative burdens associated with prior authorizations. The program allows patients using Klarity-C to switch to Vevye at a significantly reduced price, promoting adherence to prescribed treatments for dry eye disease.

Background

Access to effective treatments for dry eye disease is critical for patient outcomes, particularly given the challenges posed by prior authorizations and step therapy protocols. The introduction of programs like Vevye Access for All addresses these barriers, ensuring that patients receive the medications their healthcare providers prescribe. This initiative is particularly relevant in the context of rising healthcare costs and the need for improved patient access to essential therapies.

Data Highlights

No numerical data provided in the article.

Key Findings

• The Vevye Access for All program enables patients to switch from Klarity-C to Vevye for $59 per bottle, a 50% reduction from the market price.
• The program aims to reduce out-of-pocket costs for patients by facilitating access to prescribed medications without the need for multiple trials of different drugs.
• Harrow's initiative addresses administrative burdens related to prior authorizations, particularly for Medicare Part D patients.
• Efficient prescription management is supported through the PhilRx portal, allowing for streamlined prescription changes.
• Harrow is exploring partnerships with additional pharmacies to expand the program's reach.

Clinical Implications

Healthcare providers can leverage the Vevye Access for All program to enhance patient adherence to prescribed treatments for dry eye disease. By reducing financial and administrative barriers, this initiative may lead to improved patient outcomes and satisfaction.

Conclusion

The Vevye Access for All program represents a significant step towards improving patient access to necessary treatments for dry eye disease, addressing both cost and administrative challenges faced by patients and providers.

References

1. Retinal Physician, 2025 -- Harrow and Cencora Partner to Launch Harrow Cares Program
2. Ophthalmology Management, 2025 -- Dr. Amir H. Shojaei
3. Ophthalmology Management, 2024 -- Harrow Launches Access and Affordability Program
4. Guideline Central, 2024 -- AAO Dry Eye Syndrome Guideline Summary 2024 Preferred Practice Pattern
5. PMC, 2023 -- Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial
6. Ophthalmology Management — Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
7. AAO Dry Eye Syndrome Guideline Summary 2024 Preferred Practice Pattern - Guideline Central
8. Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial - PMC
9. Safety and Efficacy of 0.1% Cyclosporine Solutions in Dry Eye Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials - Yuri Aleksander-Ivanov, Dillan Cunha Amaral, Lidia Cheidde, Gabriel Nery Lima, Carolina Carvalho Soares Valentim, Michel Sebba Chater, Denisse J. Mora-Paez, Jaime Guedes, 2025